Related Experiment Video

Updated: Feb 19, 2026

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model
08:42

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model

Published on: July 3, 2020

5.2K

A Study of the Relationship Between Cystatin C and Metabolic Bone Disease in Preterm Infants

Sabriye Korkut1, Şeyma Memur1, Hülya Halis1

  • 1Erciyes University Faculty of Medicine, Department of Neonatology, Kayseri, Turkey

Journal of Clinical Research in Pediatric Endocrinology
|October 31, 2017
PubMed

Insights

Serum Cystatin C (CysC) levels in preterm infants are not affected by osteopenia of prematurity (OP). This finding supports the safe use of CysC as a renal insufficiency marker in these vulnerable infants.

Area of Science:

  • Neonatology
  • Pediatric Nephrology
  • Biochemistry

Background:

  • Cystatin C (CysC) is a widely recognized biomarker for assessing kidney function in premature infants.
  • Osteopenia of prematurity (OP) is a common complication in preterm infants, potentially impacting various physiological markers.
  • The reliability of CysC in infants with OP requires specific investigation.

Purpose of the Study:

  • To evaluate serum CysC levels in preterm infants diagnosed with osteopenia of prematurity (OP).
  • To determine if OP influences the accuracy and safety of using CysC as a marker for renal insufficiency in preterm neonates.

Main Methods:

  • A cohort of 50 preterm infants (gestational age ≤32 weeks) was studied.
  • Serum levels of calcium, phosphorus, alkaline phosphatase, and CysC were measured at nine weeks postnatal.
  • Bone mineral density was assessed using quantitative ultrasonography; OP was defined by a Z score of <-2.

Main Results:

  • Mean serum CysC levels were 1.50±0.19 mg/L at nine weeks postnatal.
  • No significant correlation was observed between CysC levels and bone density parameters (speed of sound, Z scores) or serum levels of calcium, phosphorus, and alkaline phosphatase.
  • Serum CysC levels did not differ significantly between infants with and without OP.

Conclusions:

  • The presence of osteopenia of prematurity does not compromise the validity of Cystatin C as a marker for renal insufficiency in preterm infants.
  • CysC remains a safe and reliable biomarker for monitoring kidney function in preterm neonates, irrespective of OP status.
Abstract

Keywords:
Cystatin Cmetabolic bone diseaseosteopeniaprematurespeed of soundrenal failure

More Related Videos

The Importance of Correct Protein Concentration for Kinetics and Affinity Determination in Structure-function Analysis19:16

The Importance of Correct Protein Concentration for Kinetics and Affinity Determination in Structure-function Analysis

Published on: March 17, 2010

21.2K
Using Real-Time Cell Metabolic Flux Analyzer to Monitor Osteoblast Bioenergetics09:43

Using Real-Time Cell Metabolic Flux Analyzer to Monitor Osteoblast Bioenergetics

Published on: March 1, 2022

3.8K

Related Concept Videos

Urinary Tract Calculi I: Introduction01:28

Urinary Tract Calculi I: Introduction

Renal calculi, or kidney stones, are solid deposits of minerals and salts formed inside the kidneys. In medical terminology, "calculus" refers to the stone itself, while "lithiasis" describes the process of stone formation. Depending on their location within the urinary system, these stones may be classified as either urolithiasis, when situated within the urinary tract, or nephrolithiasis, when located within the kidneys. Each term signifies the specific impact of the stone.Predisposition...
598
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
5.6K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
932
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
4.1K
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
3.9K
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
917